Evidence map›Paper›PMID 22836756›Full record

ArticleCancer research2012

MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFα.

Xiangming Zhang, Wooi-Loon Ng, Ping Wang, Linlin Tian, Erica Werner, Huichen Wang, Paul Doetsch, Ya Wang

Abstract read
In one paragraph

Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 180 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. RNA Therapeutics in Heart Failure.Journal of cardiovascular translational research · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis.International journal of molecular sciences · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. MicroRNAs as Regulators of Radiation-Induced Oxidative Stress.Current issues in molecular biology · 2024
    Review
  17. Inflamma-miRs Profile in Myelodysplastic Syndrome Patients.International journal of molecular sciences · 2024
    Article
  18. Review
  19. Article
  20. Review

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiangming ZhangDepartment of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Emory University, Atlanta, Georgia 30322, USA.
Wooi-Loon Ng
Ping Wang
Linlin Tian
Erica Werner
Huichen Wang
Paul Doetsch
Ya Wang
Emory University · US

Funding

A new role of MEPE/OF45 as a co-factor of CHK1 for DNA damage responseR01GM080771 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WANG, YA · 2007 to 2010
$1.4M
NIGMS NIH HHS GM080771NIGMS NIH HHS R01 GM080771
6 · The paper itself

Abstract

MicroRNA-21 (miR-21) is an oncomir overexpressed in most human tumors in that it promotes malignant growth and progression by acting on multiple targets. Here, we broaden the impact of miR-21 in cancer by showing that it regulates the formation of reactive oxygen species (ROS) that promote tumorigenesis. Key targets of miR-21 in mediating this function were SOD3 and TNFα. We found that miR-21 inhibited the metabolism of superoxide to hydrogen peroxide, produced either by endogenous basal activities or exposure to ionizing radiation (IR), by directing attenuating SOD3 or by an indirect mechanism that limited TNFa production, thereby reducing SOD2 levels. Importantly, both effects contributed to an elevation of IR-induced cell transformation. Our findings, therefore, establish that miR-21 promotes tumorigenesis to a large extent through its regulation of cellular ROS levels.

Indexed as

Cell LineCell Transformation, NeoplasticHumansMicroRNAsReactive Oxygen SpeciesReal-Time Polymerase Chain ReactionSuperoxide DismutaseTumor Necrosis Factor-alphaMicroRNAsMIRN21 microRNA, humanReactive Oxygen SpeciesSOD3 protein, humanSuperoxide DismutaseTumor Necrosis Factor-alpha

Identifiers

PMID22836756
PMCPMC3445705
OpenAlexW2128753287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.